Van Andel Research Institute findings provide more complete picture of kidney cancer
December 28, 2011 by admin · Leave a Comment
Two recent studies by Van Andel Research Institute scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments.
Research provides new kidney cancer clues
January 18, 2011 by admin · Leave a Comment
Gene mutated in 1 in 5 patients with common form of renal cancer
Grand Rapids, Mich. (January 19, 2011) In a collaborative project involving scientists from three continents, researchers have identified a gene that is mutated in one in three patients with the most common form of renal cancer. The gene called PBRM1 was found to be mutated in 88 cases out of 257 clear cell renal cell carcinomas (ccRCC) analysed, making it the most prevalent to be identified in renal cancer in 20 years.
Mayo Clinic finds early success with laser that destroys tumors with heat
October 13, 2010 by admin · Leave a Comment
JACKSONVILLE, Fla. Physicians at Mayo Clinic’s Florida campus are among the first in the nation to use a technique known as MRI-guided laser ablation to heat up and destroy kidney and liver tumors. So far, five patients have been successfully treated meaning no visible tumors remained after the procedure.
Evaluation of targeted therapy in ovarian cancer
September 30, 2010 by admin · Leave a Comment
Molecular imaging technique shows promise for monitoring early response to treatment for cisplatin-resistant ovarian tumors
Reston, Va. Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.
New tool for pre-surgical detection of kidney cancers may help patients avoid unnecessary surgeries
May 31, 2010 by admin · Leave a Comment
Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
SAN FRANCISCO, CA. (June 1, 2010)Kidney cancer is a radiographic diagnosis which means treatment decisions are often made based on the findings of a solid mass on CT or MRI. Unfortunately these tests cannot distinguish the different types of kidney cancers which have variable risks. As more Americans continue to be scanned as part of their evaluation for various ailments and symptoms, the number of kidney tumors found serendipitously has increased such that now up to 70 percent of kidney cancers are discovered incidentally.
Mayo Clinic researchers find gene they believe is key to kidney cancer
Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-0746
Mayo Clinic
JACKSONVILLE, Fla. Researchers at Mayo Clinic’s campus in Florida have discovered a key gene that, when turned off, promotes the development of common kidney cancer. Their findings suggest that a combination of agents now being tested in other cancers may turn the gene back on, providing a much-needed therapy for the difficult-to-treat cancer.
Mayo Clinic researchers find genetic secrets to common kidney cancer
May 17, 2010 by admin · Leave a Comment
Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-0746
Mayo Clinic
JACKSONVILLE, Fla. By examining expression of every human gene in clear cell renal cell carcinoma (ccRCC) compared to normal kidney cells, researchers at Mayo Clinic’s campus in Florida have discovered gene signatures they say explain much of the biology of this common and difficult-to-treat kidney cancer.
Milk and risk of renal cell cancer: Genetic research sheds new light
Contact: Tara Yates
tara.yates@aacr.org
267-646-0558
American Association for Cancer Research
PHILADELPHIA While previous research had suggested that drinking milk was related to factors that may increase the risk of renal cell cancer, results of a recent study exploiting the genetic contribution to variation in milk consumption suggest that this may not be the case.
Urine test for kidney cancer a step closer to development
April 6, 2010 by admin · Leave a Comment
Contact: Jim Dryden
jdryden@wustl.edu
314-286-0110
Washington University School of Medicine
Studying patients with kidney cancer, a team of researchers at Washington University School of Medicine in St. Louis has identified a pair of proteins excreted in the urine that could lead to earlier and more accurate diagnosis of the disease.
Drug for advanced kidney cancer shrinks tumors prior to surgery
February 16, 2010 by admin · Leave a Comment
Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina School of Medicine
Chapel Hill, N.C. - More than 57,000 Americans face a diagnosis of kidney cancer each year. Now patients with advanced disease may soon have another treatment option. Physicians who conducted a pilot study at UNC Lineberger Comprehensive Cancer Center found that therapy before surgery with the drug sorafenib can reduce the size of large tumors and could be safely undertaken administered without adding significantly to the risks of surgery.
